Health ❯ Healthcare ❯ Patient Safety ❯ Medication Risks
FDA tests found N‑nitroso‑duloxetine above the agency's interim daily limit, prompting a Class II voluntary recall that could force clinicians to change prescriptions to avoid abrupt stoppage.
